



scientific
Tides Partner.
Concept to Commercial.

Generic APIs

CPC Scientific, a subsidiary of Medtide Inc. (3880.HK), offers generic peptides as APIs for diseases such as cancer, diabetes, and obesity. Our GMP manufacturing facilities ensure compliance with global regulatory standards through rigorous quality and EHS systems. We provide regulatory support, including DMF preparation, and serve as a one-stop solution for the drug development lifecycle, from discovery to commercial manufacturing. Our expertise in Generic (ANDA) and New Chemical Entity (NCE) development, including NDA submissions, offers efficient and reliable pathways for API regulatory approval, enabling seamless transitions from concept to commercialization.

API NAME	INDICATION	EARLY R&D	LATE R&D	PROCESS VALIDATION	DMF AVAILABLE	REGULATORY FILING*
Semaglutide	<ul style="list-style-type: none"> Diabetes (type II) Obesity 					FDA: 039104 NMPA: TBD CANADA: TBD
Leuprorelin Acetate	<ul style="list-style-type: none"> Prostate and Breast Cancer Endometriosis Central Precocious Puberty 					NMPA: Y20190007496(A) (2009) MFDS: 20200625-210-J-661 (2020) TFDA: 110DMF050097
Triptorelin Acetate	<ul style="list-style-type: none"> Prostate and Breast Cancer Endometriosis Uterine Fibroids Assisted Reproduction 					NMPA: Y20170001090(A) (2019)
Terlipressin Acetate	<ul style="list-style-type: none"> Bleeding Esophageal Varices Hepatorenal Syndrome 					NMPA: Y20200000281(A) EDQM: R0-CEP 2020-111
Cetrorelix Acetate	<ul style="list-style-type: none"> In Vitro Fertilization (IVF) 					NMPA: Y20190001147 (A) FDA: 034884
Goserelin Acetate	<ul style="list-style-type: none"> Prostate and Breast Cancer Endometriosis Uterine Fibroids ART 					NMPA: Y20230000413 (A)
Linaclotide	<ul style="list-style-type: none"> Irritable Bowel Syndrome with Constipation (IBS-C) Chronic Idiopathic Constipation (CIC) 					NMPA: Y20210000906
Triptorelin Pamoate	<ul style="list-style-type: none"> Endometriosis Uterine Fibroids Premature Puberty Prostate Cancer ART 					NMPA: Q4 2025
Tirzepatide	<ul style="list-style-type: none"> Diabetes (type II) Obesity 					FDA: Q1 2026
Teduglutide	<ul style="list-style-type: none"> Short Bowel Syndrome 					FDA: Q2 2026
Difelikefalin	<ul style="list-style-type: none"> Chronic Kidney Disease-associated Pruritus (CKD-aP) 					NMPA: Q1 2026
Etelcalcetide	<ul style="list-style-type: none"> Secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy 					NMPA: Q4 2026
Plecanatide	<ul style="list-style-type: none"> Chronic Idiopathic Constipation (CIC) Irritable Bowel Syndrome with Constipation (IBS-C) 					Pilot Testing Completed

*Subject to change.



scientific

Tides Partner.
Concept to Commercial.

A subsidiary of Medtide Inc. (3880.HK)



WHO WE ARE

FOUNDED IN 2001

Established in 2001, CPC Scientific is a globally recognized leader in synthetic peptide production, serving as a trusted CRDMO (Contract Research, Development, and Manufacturing Organization). To further support the biotechnology and pharmaceutical industries, we have expanded our expertise to include synthetic oligonucleotides. Our extensive portfolio features custom, generic, and commercial peptides, carefully tailored to meet the diverse and evolving needs of our clients worldwide.



Complete Life Cycle Support:

Supporting clients from early drug discovery through clinical trials to commercial manufacturing.



Global Expertise:

Proudly supplying generic and commercial APIs to partners worldwide. Facilities in Hangzhou (China) and Rocklin (U.S.) to meet worldwide demands.



State-of-the-Art Facilities:

Equipped with dozens of isolated process and purification suites, enabling simultaneous multi-kg batch production.



Regulatory Excellence:

Adhere rigorously to CGMP as mandated by major regulatory authorities globally, including FDA, NMPA, EMA, MFDS, TGA.

WHY CPC SCIENTIFIC?

For over two decades, CPC Scientific has been a reliable partner to their clients all over the world including multinational pharmaceutical companies, biotech companies and academic institutions providing value-added one-stop-shop development and manufacturing services to support their clinical, generic, and commercial efforts. CPC Scientific has been successfully supplying generic and commercialized APIs to their clients in the U.S., Europe Australia, Japan and China for their peptide-based drugs and medical devices. By expanding our GMP manufacturing footprint, we will enable our clients to have multiple geographic options to ensure a secure API supply chain.

NEW FACILITY



OUR NEW ROCKLIN CGMP FACILITY

Location: 3880 Atherton Rd, Rocklin, CA 95765

- Opening soon!
- 41,000 square feet of cutting-edge manufacturing space.
- Increased capacity to meet the growing demand for peptide-based therapeutics.
- Diversifies CPC Scientific's supply chain to ensure security and reliability.

MESSAGE FROM THE CEO



"We have helped many of our clients bring innovative drugs to the market from concept to reality. With the new Rocklin site, we aim to expand our support to the North American market and continue leveraging decades of peptide synthesis expertise to save lives and improve global health."

— Shawn Lee, PhD, CEO

📍 3880 Atherton Rd, Rocklin, CA 95765

📍 1900 McCarthy Blvd, Suite 204, Milpitas, CA 95035



www.cpcscientific.com



sales@cpcscientific.com



+1 408-734-3800



+1 408-734-3810